The use of blood plasma and not serum is recommended for the analysis of EV, unless the study aim involves the investigation of platelet‐derived EV. The use of ACD‐A, citrate or EDTA is recommended for the analysis of EV in blood plasma for a BPI up to 1 h after sample collection; while only ACD‐A or EDTA are recommended for a BPI up to 8 h after sample collection. The use of ACD‐A or EDTA is recommended for omics profiling of blood plasma EV; whether these omics profiles remain stable with increased BPI to ensure confident biomarker analysis requires further investigation. Preservation BCT can be used for the analysis of EV in blood plasma, but their use has no advantage compared to non‐preservation BCT following short or long BPI. For specific research questions, an informed selection of the most optimal combination of BCT and BPI can be made based upon performance metric profiles. Performance metrics that can be implemented to evaluate the performance of BCT and BPI include analysis of (1) platelet activation, (2) activated platelet EV and non‐platelet EV, (3) residual platelets, (4) EV recovery, (5) erythrocyte EV, (6) molecular signatures. Workflow standardization and transparent reporting of pre‐analytic variables, including BCT and BPI, is mandatory